BR112022018452A2 - Proteínas de ligação multiespecíficas e métodos de desenvolvimento das mesmas - Google Patents

Proteínas de ligação multiespecíficas e métodos de desenvolvimento das mesmas

Info

Publication number
BR112022018452A2
BR112022018452A2 BR112022018452A BR112022018452A BR112022018452A2 BR 112022018452 A2 BR112022018452 A2 BR 112022018452A2 BR 112022018452 A BR112022018452 A BR 112022018452A BR 112022018452 A BR112022018452 A BR 112022018452A BR 112022018452 A2 BR112022018452 A2 BR 112022018452A2
Authority
BR
Brazil
Prior art keywords
binding proteins
methods
developing
multispecific binding
antigen
Prior art date
Application number
BR112022018452A
Other languages
English (en)
Inventor
chai Qing
Wu Xiufeng
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112022018452A2 publication Critical patent/BR112022018452A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROTEÍNAS DE LIGAÇÃO MULTIESPECÍFICAS E MÉTODOS DE DESENVOLVIMENTO DAS MESMAS. A presente invenção refere-se a proteínas de ligação multiespecíficas que se ligam a um primeiro antígeno e a um segundo antígeno e a métodos de purificação de proteínas de ligação multiespecíficas.
BR112022018452A 2020-03-25 2021-03-18 Proteínas de ligação multiespecíficas e métodos de desenvolvimento das mesmas BR112022018452A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994509P 2020-03-25 2020-03-25
PCT/US2021/022935 WO2021194839A1 (en) 2020-03-25 2021-03-18 Multispecific binding proteins and methods of developing the same

Publications (1)

Publication Number Publication Date
BR112022018452A2 true BR112022018452A2 (pt) 2022-11-01

Family

ID=75478220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018452A BR112022018452A2 (pt) 2020-03-25 2021-03-18 Proteínas de ligação multiespecíficas e métodos de desenvolvimento das mesmas

Country Status (11)

Country Link
US (1) US20230242671A1 (pt)
EP (1) EP4126929A1 (pt)
JP (1) JP2023525444A (pt)
KR (1) KR20220156912A (pt)
CN (1) CN115605506A (pt)
AU (1) AU2021241426A1 (pt)
BR (1) BR112022018452A2 (pt)
CA (1) CA3173162A1 (pt)
IL (1) IL296428A (pt)
MX (1) MX2022011847A (pt)
WO (1) WO2021194839A1 (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006316629A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013088259A2 (en) 2011-10-19 2013-06-20 Novimmune S.A. Methods of purifying antibodies
DK2825559T3 (da) 2012-03-13 2019-06-03 Novimmune Sa Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat
WO2014150973A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
CN109475642B (zh) * 2016-06-10 2023-05-02 卫材R&D管理有限公司 赖氨酸缀合的免疫球蛋白
BR112019025612A2 (pt) * 2017-06-05 2020-06-16 Janssen Biotech, Inc. Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos

Also Published As

Publication number Publication date
AU2021241426A1 (en) 2022-10-06
WO2021194839A1 (en) 2021-09-30
KR20220156912A (ko) 2022-11-28
JP2023525444A (ja) 2023-06-16
CA3173162A1 (en) 2021-09-30
US20230242671A1 (en) 2023-08-03
MX2022011847A (es) 2023-01-04
CN115605506A (zh) 2023-01-13
EP4126929A1 (en) 2023-02-08
IL296428A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CO2019009076A2 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
UY37027A (es) PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO de Anti-TL1A/Anti-TNF-a Y SUS USOS
EA201891165A1 (ru) Молекулы, связывающие pd1 и/или lag3
BR112018067458A2 (pt) anticorpos para tigit
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
ECSP13012525A (es) Anticuerpos contra metaloproteasa-9 de matriz.
BR112013021562A2 (pt) anticorpos para cd70
BR112014021477A2 (pt) anticorpos para metaloproteinase de matriz 9
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
BR112022008730A2 (pt) Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo
BR112022023117A2 (pt) Constructos de anticorpos de domínio único neutralizantes de sars-cov2
BR112013004594A2 (pt) método para a determinação de um conteúdo de antígeno
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
BR112021026309A2 (pt) Anticorpos para ativação de células t
BR112022018452A2 (pt) Proteínas de ligação multiespecíficas e métodos de desenvolvimento das mesmas
BR112022004302A2 (pt) Anticorpos anti-il-27 e usos dos mesmos
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения